Lisata Slashes 72% of Workforce, CMO Out, Sues Kuva Labs After Failed Merger
LSTA is trading near its 52-week low of $0.988 (1.3% above the low) on elevated volume (1.9× avg).
Summary
Lisata Therapeutics announced a 72% workforce reduction, terminated its Chief Medical Officer, and filed a lawsuit against Kuva Labs for breaching the merger agreement. The company is pursuing strategic options amid a going-concern warning.
Key Events · Executive and Board Changes · LSTA
-
72% Workforce Reduction
In a drastic cost-cutting move, the board approved the immediate layoff of approximately 72% of employees, aiming to preserve cash and maximize shareholder value while the company explores strategic options.
-
Chief Medical Officer Terminated
Dr. Kristen K. Buck, EVP of R&D and CMO, was terminated without cause. She is entitled to 12 months' salary and bonus plus COBRA coverage.
-
$1.2M in Severance Costs
The company estimates it will incur approximately $1.2 million in severance and termination benefits, to be recognized through Q3 2026.
-
Retention Bonus for CAO
To retain key financial leadership, the board approved a $200,000 cash retention bonus for James Nisco, SVP Finance and CAO, payable if he remains with the company through December 31, 2026.
Analysis · LSTA · Life Sciences
Lisata Therapeutics is in crisis mode. The company just cut nearly three-quarters of its staff, fired its Chief Medical Officer, and is suing its would-be acquirer Kuva Labs for breach of contract. This follows the collapse of the $4.00-per-share tender offer last month, which left Lisata with a going-concern warning and dwindling cash. The $1.2 million in severance costs will further strain resources. The retention bonus for the Chief Accounting Officer suggests an attempt to keep key financial personnel during a strategic review, but the mass layoff signals a company fighting for survival. With the stock trading near its 52-week low of $0.99, the market is pricing in severe distress.
At the time of this filing, LSTA was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.99 to $5.07. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.